Page last updated: 2024-10-30

memantine and Clasp-Knife Spasticity

memantine has been researched along with Clasp-Knife Spasticity in 6 studies

Research Excerpts

ExcerptRelevanceReference
"We report the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks."9.14A randomized trial of memantine as treatment for spasticity in multiple sclerosis. ( Goodman, AD; McDermott, MP; Mehta, LR; Schwid, SR, 2010)
"We report the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks."5.14A randomized trial of memantine as treatment for spasticity in multiple sclerosis. ( Goodman, AD; McDermott, MP; Mehta, LR; Schwid, SR, 2010)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19902 (33.33)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kasatkin, DS1
Mehta, LR1
McDermott, MP1
Goodman, AD1
Schwid, SR1
Grossmann, W1
Schütz, W1
Rösche, J1
Schwarz, M1
Block, F1
Sontag, KH1
Mundinger, F1
Milios, E1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Memantine for Spasticity in MS Patients[NCT00638027]Phase 421 participants (Actual)Interventional2006-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Multiple Sclerosis Functional Composite (MSFC) Score Between Baseline and Week 12

"9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity function. Timed 25-Foot Walk (T 25 FW) is a quantitative measure of lower extremity function. The patient is instructed to walk 25 feet as quickly as possible, but safely.~Paced Auditory Serial Addition Test-3 seconds (PASAT-3) is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability.~The MSFC is based on the concept that scores for these 3 dimensions-arm, leg, and cognitive function are combined to create a single score that can be used to detect change over time in a group of MS patients. This is done by creating Z-scores for each component of the MSFC. Implicit in this approach is the idea that patients who deteriorate or improve on all 3 component measures will have an overall larger change than patients who change on only 1 of the 3 measures. The MSFC score was transformed to z-scores, with higher scores indicating better outcome." (NCT00638027)
Timeframe: Baseline, Week 12

InterventionZ score (Mean)
Memantine0.02
Placebo-0.04

Difference in Ashworth Spasticity Scale Score Between Baseline and 12 Weeks

"spasticity scale score: the most common used tool to measure the degree of spasticity of the lower extremities.~Score: Degree of Muscle Tone 0: no increase in tone~slight increase in tone 1+: slight increase in tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of motion.~more marked increase in muscle tone through most of the range of movement, but affected part(s) easily moved.~considerable increase in muscle tone, passive movement difficult.~affected part(s) rigid in flexion or extension." (NCT00638027)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Mean)
Memantine-1.55
Placebo-1.00

Difference in the Multiple Sclerosis Spacticy Scale (MSSS-88) Between Baseline and 12 Weeks

"Multiple Sclerosis Spacticy Scale (MSSS-88) is a patient reported questionnaire rating scale to quantify the perspectives of the impact of spasticity on people with multiple sclerosis.~Scoring: Individual items are scored on a 4 point Likert scale: 1 (Not bothered at all), 2 (a little bothered), 3 (moderately bothered), 4 (extremely bothered).This questionnaire asks how bothered you have been by your spasticity in the past two weeks. By spasticity we mean muscle stiffness and spasms.The MSSS-88 is a reliable and valid, patient-based, interval-level measure of the impact of spasticity in multiple sclerosis. Scores were summed, without weighting or standardization, to generate ordinal-level total scores just as any other Likert-type scale. Missing responses to items can be replaced with the mean score of the items completed (person-specific item mean score) provided that 50% or more of the items in a scale have been completed. The range is 8-32 and higher scores mean poorer outcome." (NCT00638027)
Timeframe: baseline, 12 weeks

Interventionunits on a scale (Mean)
Memantine-5.55
Placebo-3.33

Trials

1 trial available for memantine and Clasp-Knife Spasticity

ArticleYear
A randomized trial of memantine as treatment for spasticity in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2010, Volume: 16, Issue:2

    Topics: Adult; Disability Evaluation; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans

2010

Other Studies

5 other studies available for memantine and Clasp-Knife Spasticity

ArticleYear
[Pathogenetic therapy of spasticity].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008, Volume: 108, Issue:3

    Topics: Adult; Aged; Animals; Cerebral Palsy; Child; Controlled Clinical Trials as Topic; Dantrolene; Diseas

2008
[Memantine and neurogenic bladder disorders within the bounds of spastic conditions].
    Arzneimittel-Forschung, 1982, Volume: 32, Issue:10

    Topics: Adult; Aged; Amantadine; Electromyography; Female; Humans; Male; Memantine; Middle Aged; Muscle Spas

1982
Treatment of spasticity.
    Spinal cord, 2002, Volume: 40, Issue:6

    Topics: Acetates; Amines; Aminopyridines; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Clonidine; Cy

2002
N-methyl-D-aspartate (NMDA)-mediated muscle relaxant action of memantine in rats.
    Neuroscience letters, 1992, Aug-31, Volume: 143, Issue:1-2

    Topics: Animals; Electromyography; Female; Male; Memantine; Muscle Relaxation; Muscle Spasticity; N-Methylas

1992
[Experiences with memantine in the treatment of severe spastic and extrapyramidal movement disorders in combination with stereotaxic surgery].
    Der Nervenarzt, 1985, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Aged; Amantadine; Athetosis; Basal Ganglia Diseases; Cerebral Palsy; Child; Chore

1985